Tonix Pharmaceuticals Holding Corp TNXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $12.20
- Day Range
- $11.91–12.78
- 52-Week Range
- $10.03–69.90
- Bid/Ask
- $11.89 / $12.03
- Shares Outstanding
- 15.94M
- Market Cap
- $190.33M
- Volume/Avg
- 203,976 / 489,718
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.76
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 142
- Website
- https://www.tonixpharma.com
Valuation
|
Metric
|
TNXP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.71 |
Price/Sales | 6.76 |
Price/Cash Flow | — |
Price/Earnings
TNXP
Financial Strength
|
Metric
|
TNXP
|
|---|---|
Quick Ratio | 6.68 |
Current Ratio | 6.99 |
Interest Coverage | — |
Quick Ratio
TNXP
Profitability
|
Metric
|
TNXP
|
|---|---|
Return on Assets (Normalized) | −60.06% |
Return on Equity (Normalized) | −66.68% |
Return on Invested Capital (Normalized) | −68.73% |
Return on Assets
TNXP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| argenx SE ADR
ARGX
| Tbkpnnfw | Stmv | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qyhwmtn | Hkfdgh | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| Rcwdcnt | Hzwq | $30B | |||
| Moderna Inc
MRNA
| Bxjjsgs | Yyml | $25B | |||
| Royalty Pharma PLC Class A
RPRX
| Wzyqsrrjq | Tjjfh | $24B | |||
| BioNTech SE ADR
BNTX
| Gxfbvrrkl | Vwrtp | $23B | |||
| Incyte Corp
INCY
| Ygnygzlfz | Cpv | $20B | |||
| BioMarin Pharmaceutical Inc
BMRN
| Zygbmzz | Szgtp | $11B | |||
| Bio-Techne Corp
TECH
| Bwtxnddk | Lnwnytq | $9B | |||
| CRISPR Therapeutics AG
CRSP
| Vnswdnmz | Qst | $5B |
United States